Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with diverse actions, including strong neurotrophic and neuroprotective effects. The aim of our present review is to provide a summary of the different approaches how in vivo neuroprotective effects can be achieved, emphasizing the potential translational values for future therapeutic applications. In the central nervous system, PACAP has been shown to have in vivo protective effects in models of cerebral ischemia, Parkinson’s and Alzheimer’s disease, Huntington chorea, traumatic brain and spinal cord injury and different retinal pathologies. PACAP passes through the bloodbrain barrier and therefore, systemic administration can affect the nervous system and lead to neuroprotective effects. This review summarizes results obtained in neuronal injury studies via local, such as intracerebral, intrathecal, intracerebroventricular, intravitreal and systemic treatments, such as intravenous, intraperitoneal and subcutaneous administration of PACAP. A few other options are summarized, like intranasal and eye drops treatments, as well as difficulties and side effects of different treatments are also discussed.
Keywords: Intracerebroventricular, intravenous, intranasal, topical, intravitreal, Pituitary adenylate cyclase activating polypeptide (PACAP).
Current Pharmaceutical Design
Title:Alternative Routes of Administration of the Neuroprotective Pituitary Adenylate Cyclase Activating Polypeptide
Volume: 24 Issue: 33
Author(s): Dora Reglodi*, Tamas Atlasz, Adel Jungling, Edina Szabo, Petra Kovari, Sridharan Manavalan and Andrea Tamas
Affiliation:
- Department of Anatomy, MTA-PTE PACAP Research Team, Centre for Neuroscience, University of Pecs Medical School, Pecs,Hungary
Keywords: Intracerebroventricular, intravenous, intranasal, topical, intravitreal, Pituitary adenylate cyclase activating polypeptide (PACAP).
Abstract: Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with diverse actions, including strong neurotrophic and neuroprotective effects. The aim of our present review is to provide a summary of the different approaches how in vivo neuroprotective effects can be achieved, emphasizing the potential translational values for future therapeutic applications. In the central nervous system, PACAP has been shown to have in vivo protective effects in models of cerebral ischemia, Parkinson’s and Alzheimer’s disease, Huntington chorea, traumatic brain and spinal cord injury and different retinal pathologies. PACAP passes through the bloodbrain barrier and therefore, systemic administration can affect the nervous system and lead to neuroprotective effects. This review summarizes results obtained in neuronal injury studies via local, such as intracerebral, intrathecal, intracerebroventricular, intravitreal and systemic treatments, such as intravenous, intraperitoneal and subcutaneous administration of PACAP. A few other options are summarized, like intranasal and eye drops treatments, as well as difficulties and side effects of different treatments are also discussed.
Export Options
About this article
Cite this article as:
Reglodi Dora *, Atlasz Tamas , Jungling Adel , Szabo Edina , Kovari Petra, Manavalan Sridharan and Tamas Andrea , Alternative Routes of Administration of the Neuroprotective Pituitary Adenylate Cyclase Activating Polypeptide, Current Pharmaceutical Design 2018; 24 (33) . https://dx.doi.org/10.2174/1381612824666181112110934
DOI https://dx.doi.org/10.2174/1381612824666181112110934 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Inhalation Cough Challenge
Current Respiratory Medicine Reviews Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology The Urocortins: Mechanisms of Cardioprotection and Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Glutamate Binding-Site Ligands of NMDA Receptors
Current Medicinal Chemistry Tubulin-Independent Tau in Alzheimer’s Disease and Cancer: Implications for Disease Pathogenesis and Treatment
Current Alzheimer Research Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research Metabolic Control of Glia-Mediated Neuroinflammation
Current Alzheimer Research COX-2 and mPGES in Brain Endothelial Cells: Potential Targets of Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Glutamatergic Neurotransmission As Molecular Target of New Anticonvulsants
Current Topics in Medicinal Chemistry Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology GSK3 Inhibitors and Disease
Mini-Reviews in Medicinal Chemistry EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Carbon Monoxide - Toxicity of Low-Dose Application
Current Pharmaceutical Biotechnology